Friday 16 October 2026
Export ALEC’s income statement to Excel — free account
Alector, Inc.
ALEC Healthcare Biotechnology
Alector, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $21.0 million, down 79.1% from fiscal 2024. In the quarter to June 2026, revenue fell 57.8%, EPS grew 30.0%, free cash flow grew 30.2% and total debt rose 3.27%, each against the same quarter a year earlier.
1.84
0.07
−3.66%
Follow ALEC
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | 2 | 1 | 3 | 5 | 3 | 1 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(5.15) | (2.20) | (0.68) | 0.32 | 2.17 | 1.62 | 2.08 | — | — | — |
P/S ratio |
7.64 | 1.82 | 6.89 | 5.62 | 8.02 | 55.76 | 50.13 | 7.67 | 7.67 | 7.67 |
Altman Z″-Score (non-manufacturers) |
(9.85) | (3.26) | (0.98) | 2.09 | 3.43 | 0.60 | 1.97 | 3.37 | 4.05 | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 5.62 | 0.00 | 0.00 | 1.69 | 1.69 | 1.69 |
Beneish M-Score |
— | — | — | (3.91) | — | — | — | — | — | — |
P/Operating CF |
(3.85) | (3.32) | (14.52) | (15.34) | (33.71) | (24.69) | (36.90) | (12.03) | (12.03) | (12.03) |
P/B ratio |
5.24 | 1.44 | 4.99 | 3.50 | 5.52 | 4.40 | 5.46 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
5.24 | 1.44 | 4.99 | 3.50 | 5.52 | 4.40 | 5.46 | 0.00 | 0.00 | 0.00 |
EV/Sales |
(4.07) | (2.12) | 1.65 | 0.61 | 4.70 | 38.60 | 35.75 | (2.82) | (2.82) | (2.82) |
EV/EBITDA |
0.56 | 1.42 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.39 | 1.39 | 1.39 |
EV/Operating CF |
0.47 | 0.93 | (0.87) | (3.98) | 3.26 | (4.88) | (7.64) | (0.61) | (0.61) | (0.61) |
EV/FCF |
0.47 | 0.92 | (0.86) | (3.31) | 3.29 | (4.74) | (6.62) | (0.62) | (0.62) | (0.62) |
Quick Ratio |
3.68 | 3.31 | 3.08 | 7.63 | 5.32 | 6.07 | 5.70 | 6.06 | 8.49 | 33.81 |
Current Ratio |
3.83 | 3.40 | 3.18 | 7.74 | 5.37 | 6.19 | 5.77 | 6.11 | 8.50 | 33.90 |
Net Debt/EBITDA |
1.61 | 2.68 | 3.47 | 5.13 | 25.52 | 1.93 | 2.80 | 5.16 | 1.01 | 3.40 |
Debt/Assets |
3.30% | 2.00% | 0.00% | 5.50% | 5.84% | 10.50% | 11.39% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.32 | 0.07 | 0.00 | 0.20 | 0.16 | 0.19 | 0.25 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.06 | 0.18 | 0.14 | 0.17 | 0.32 | 0.05 | 0.06 | 0.10 | 0.03 | 0.00 |
Operating CF/Net income |
1.29 | 1.93 | 1.41 | 0.15 | (8.22) | 0.88 | 0.94 | (2.44) | 0.55 | 0.86 |
Capex/Depreciation |
(0.01) | 0.23 | 0.37 | (0.56) | (0.31) | (0.64) | (2.74) | (1.85) | (1.18) | (11.19) |
| (181.56%) | (91.24%) | (74.81%) | (51.75%) | (12.79%) | (82.30%) | (216.52%) | 69.93% | 84.43% | 39.28% | |
| (37.54%) | (21.84%) | (18.50%) | (16.64%) | (5.58%) | (41.80%) | (28.86%) | (19.19%) | (27.52%) | (12.80%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(68.79%) | (37.57%) | (31.82%) | (20.26%) | (5.70%) | (49.59%) | (32.00%) | (20.40%) | (15.59%) | (28.94%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 7.07 | 13.03 | 0.00 | 0.00 | 0.00 | 19,568.10 | 191.27 |
Research and Development Expense of Revenue |
584.77% | 184.91% | 197.93% | 157.48% | 91.46% | 743.53% | 473.76% | 263.87% | 800.83% | 3,287.02% |
Selling, General and Administrative Expense of Revenue |
256.53% | 59.28% | 58.40% | 45.68% | 26.58% | 281.56% | 165.39% | 43.12% | 174.11% | 450.48% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
126.67% | 39.24% | 44.09% | 34.54% | 19.69% | 144.67% | 76.73% | 25.02% | 143.35% | 471.88% |
Graham Net Nets |
0.02 | 0.46 | 0.12 | 0.20 | 0.14 | 0.17 | 0.12 | 0.46 | 0.46 | 0.46 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.28 | 0.00 | 0.00 |
Earnings Yield |
(89.10%) | (65.08%) | (19.40%) | (17.69%) | (2.28%) | (16.13%) | (9.87%) | (25.40%) | (25.40%) | (25.40%) |
Free Cash Flow Yield |
(114.56%) | (126.63%) | (27.88%) | (3.26%) | 17.78% | (14.60%) | (10.77%) | 59.15% | 59.15% | 59.15% |
Revenue per Share |
0.20 | 1.04 | 1.16 | 1.62 | 2.58 | 0.27 | 0.34 | 2.45 | 0.41 | 0.06 |
Operating CF per Share |
(1.79) | (2.38) | (2.20) | (0.25) | 3.71 | (2.14) | (1.61) | 11.28 | (1.94) | (1.81) |
Capex per Share |
0.00 | (0.01) | (0.03) | (0.05) | (0.04) | (0.06) | (0.25) | (0.17) | (0.09) | (0.31) |
Free Cash Flow per Share |
(1.79) | (2.39) | (2.23) | (0.30) | 3.67 | (2.21) | (1.86) | 11.11 | (2.03) | (2.13) |
Cash per Share |
2.49 | 4.28 | 6.55 | 8.64 | 9.14 | 5.32 | 5.72 | 25.69 | 3.55 | 7.09 |
Shareholders Equity per Share |
0.30 | 1.31 | 1.60 | 2.60 | 3.74 | 3.44 | 3.15 | 10.01 | 2.78 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.30 | 1.31 | 1.60 | 2.60 | 3.74 | 3.44 | 3.15 | 10.01 | 2.78 | 0.00 |
Free Cash Flow |
(184.07) | (231.16) | (186.54) | (24.45) | 295.30 | (171.77) | (114.57) | 125.58 | (18.57) | (15.24) |
Working Capital |
196.95 | 299.76 | 387.86 | 632.63 | 610.16 | 353.42 | 295.47 | 245.23 | 205.57 | 49.68 |
Capital Expenditures |
(0.04) | (1.25) | (2.38) | (4.12) | (3.25) | (5.03) | (15.26) | (1.88) | (0.80) | (2.25) |
Net Current Asset Value |
3.86 | 83.31 | 78.14 | 153.23 | 235.78 | 200.79 | 130.27 | 97.94 | 22.37 | 51.19 |
EV/EBIT |
0.55 | 1.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36 | 1.36 | 1.36 |
Capex to Sales |
0.00 | 0.01 | 0.02 | 0.03 | 0.02 | 0.24 | 0.72 | 0.07 | 0.21 | 5.41 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.31 | (0.32) | (0.30) | 0.29 | 0.38 | 0.26 | 0.16 | 0.09 | 0.24 | 0.08 |
Cash ROIC |
(62.11%) | (42.06%) | (27.31%) | (2.52%) | 27.25% | (23.46%) | (19.23%) | 31.12% | (32.07%) | (29.98%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 26.78 | 1.99 | 0.00 | 0.00 | 0.00 | 0.04 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | — | — | — |
Average Receivables |
— | — | — | 4.99 | 103.81 | — | — | — | 100.23 | 100.23 |
Average Payables |
1.95 | 3.00 | 3.98 | 4.47 | 3.88 | 1.64 | 0.20 | 0.63 | 1.15 | 1.15 |
Average Assets |
380.77 | 545.07 | 704.74 | 801.15 | 651.45 | 455.08 | 365.14 | 272.21 | 118.03 | 118.03 |
Average Common Equity |
78.72 | 130.48 | 174.30 | 257.58 | 284.13 | 231.14 | 48.67 | (74.72) | (38.47) | (38.47) |
Columns are period end dates